PATENT CLAIM ANALYSIS

Application Number: 16082325
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "329000"]

Abstract:
The present invention provides for a method of treating cancer and/or reducing proliferation of cancer cells, the method comprising administering to a subject in need of such treatment a composition comprising a PIM kinase inhibitor that exhibits changes of mRNA splicing in combination with a compound that modulates/inhibits activity of an RNA splicing factor protein. Further, changes in splicing of mRNAs and phosphorylation of RNA splicing factors can be used as biomarkers for patient responsiveness to anti-PIM treatment and also suggest effective combinatorial therapies, including synergistic combination.

Claim (Index 10):
A composition for regulating splicing factors to treat cancer, the composition comprising a PIM kinase inhibitor that exhibits changes and/or disruption of mRNA splicing in combination with a compound that modulates/inhibits splicing activity of an RNA splicing factor.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 97.0
- Lexical Diversity: 1.46032
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12130373', '13584369', '12757931', '12757930', '12757934']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7470881956453491
- 35 USC 102 Novelty (BERT): 0.5009859067364925
- Combined Prediction Score: 0.7224779667544634
- Mean Citation Score: 188.945326
- Max Citation Score: 194.43251
- Similarity Product: 115.9200693421215

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test